Resolution of Intraocular Lens Precipitates with Topical Corticosteroids

Tanner J Ferguson, MD, Jordan D Deaner, MD, Craig See, MD, and Careen Y Lowder, MD, PhD*

Uveitis Department, Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA

*Corresponding author: Careen Y Lowder, MD, PhD, Uveitis Department, Cole Eye Institute, Cleveland Clinic 9500 Euclid Avenue i-32, Cleveland, OH 44195, USA

Abstract

Background: Postoperative inflammatory cell deposition on the surface of intraocular lenses (IOLs) is a well-described entity and considered part of the normal postoperative course. This inflammatory response, which is usually a visually insignificant finding, typically begins shortly after surgery and peaks at 3 months.

Case: We describe a case of a patient who developed late-onset intraocular lens (IOL) cellular precipitates 8 months after IOL placement. The patient had a history of clinically inactive toxoplasmosis and developed visually significant IOL precipitates 8 months after uncomplicated cataract surgery with a previously unremarkable postoperative course without other signs of ocular inflammation. The IOL deposits improved and resolved with use of topical steroids, which coincided with an improvement in visual acuity.

Conclusions: The results of this case suggest that a trial of topical steroid therapy should be considered in patients presenting with late-onset precipitates on the surface of IOLs, even in the absence of concomitant intraocular inflammation.

Introduction

Postoperative deposition of inflammatory cells on the surface of intraocular lenses (IOLs) is a well-described phenomenon after cataract surgery and are typically of no clinical significance [1,2]. The cellular deposits, or precipitates, are thought to represent a normal component of the eye’s foreign body response to the implanted IOL [3]. This inflammatory response consists of small, fibroblast-like cells early in the postoperative period (e.g. 1 month) and a giant cell deposition that begins early in the postoperative period and peaks at 3 months [4]. A study by Werner, et al. noted a variation in the magnitude and timing of the cellular inflammatory response dependent upon the various IOL materials [5,6]. Numerous risk factors have been identified for inflammatory giant-cell deposit (IGCD) formation including older generation silicone IOLs and presence of posterior synechiae.

Although rare, visually significant IOL changes are a concern for both surgeons and their patients as IOL removal or exchange can be a complex or potentially complicated procedure, particularly in patients with a history of uveitis [7]. We present a case of visually significant localized cellular deposits on the surface of an IOL in a patient with clinically inactive toxoplasmosis that presented late in the postoperative period and resolved with topical corticosteroids.

Case Description

A 41-year-old man presented with a complaint of slowly worsening vision in his right eye (OD) 8 months after cataract surgery. His past ocular history was significant for uncomplicated cataract extraction with IOL placement in the capsular bag OD and bilateral congenital toxoplasmosis chorioretinitis on prophylactic double-strength trimethoprim/sulfamethoxazole 3 times per week. His chorioretinitis had been inactive for at least 9 years when he first established care at our institution, without clinical evidence of intraocular inflammation prior to surgery. Post-operatively his course was unremarkable with a BCVA of 20/30 and no signs of ocular inflammation at 1- and 3-months after surgery, off of topical corticosteroids. On the day of presentation, his ocular examination revealed a decrease in visual acuity to 20/40 OD. His vision remained stable at 20/80 in his left eye (OS). Intraocular pressure was normal in both
right eye and asked to return in 14 days. On follow-up examination, the deposits had markedly improved (Figure 2). The patient was continued on topical steroid drops QID in an effort to fully resolve the deposits. The patient followed up 4 weeks later and endorsed subjective improvement in vision. Examination noted a return of BCVA to 20/30. Moreover, the exam demonstrated continued improvement in the deposits on the surface of IOL (Figure 3). At the follow-up visit 6 months after initially presenting with the inflammatory cell deposits, the patient's IOL remained clear with stable BCVA maintained on a topical steroid once daily.

Discussion

Post-operative IOL cellular deposits are rarely clinically significant and can remain on the lens up
The cellular precipitates reported in our case are unique from what has been previously reported in the literature. As previously mentioned, inflammatory IOL deposits typically occur in the early postoperative period and begins to dissipate after 3 months [8]. In the presently described case, the patient underwent uncomplicated cataract surgery and successful implantation of a hydrophilic, acrylic IOL with an uncomplicated postoperative course. He was able to be tapered off a standard regimen of postoperative steroid drops without a recurrence of inflammation and a notably clear IOL was reported at 1 month post-operatively. At 8 months post-operatively, he spontaneously presented with new, visually significant, white deposits on the anterior surface of the IOL. Although the patient had a history of uveitis, his exam was absent of anterior and posterior inflammation. Samuelson, et al. described the development of giant-cell deposits on IOLs after combined cataract and glaucoma surgery in the absence of other signs of intraocular inflammation, but only when adjacent to posterior synechiae, which was not present in our case [13]. This pattern of late-onset inflammatory giant cell deposits after a previously clear IOL is unique from the normal postoperative foreign-body response with a peak in the giant-cell response early in the postoperative period [4,5,8]. Given the absence of associated inflammation and posterior synechiae, we suspect that there are host-specific factors potentially related to the history of congenital toxoplasmosis chorioretinitis that contributed to the cellular deposition on the surface of the IOL. The decision to initiate topical corticosteroids was made based on the patient’s history of uveitis and hesitation to pursue surgical intervention given his poor vision in the contralateral eye. The patient had an excellent re-

Figure 3: This figure demonstrates the appearance of the IOL 4 weeks after initial presentation. There is a marked improvement in the appearance of the IOL compared to the initial presentation with near complete resolution of the deposits and vision restored to baseline.
response to topical corticosteroids with near complete resolution of the deposits, despite lacking other signs of intraocular inflammation. Although our case does not include microscopic examination of the deposits, given the patient’s history of uveitis and response to steroid, we suspect that these deposits were inflammatory in nature.

In summary, we present a case of presumed inflammatory IOL deposits that demonstrated excellent improvement and response to topical steroid therapy alone. Our cases suggest that a trial of topical steroid therapy should be considered in patients presenting with late-onset IOL deposits, even in the absence of other signs of intraocular inflammation, particularly if the patient has a history of uveitis.

Acknowledgments

Ethics approval

This study has been performed in accordance with the Declaration of Helsinki. As a single case, no formal human subjects research review was required by the institution.

Consent for publication

Written and signed consent was obtained from the patient for permission of publication of this case report.

Authors’ contributions

All authors have read and approved the final manuscript. All authors equally participated in the drafting of the manuscript and review of the literature.

Competing interests

Authors declare they have no competing interests.

Funding

This study had no funding.

References

1. Yamanaka A, Kazusa R, Takayama S (1989) Cells on the various kinds of intraocular lens implants. Eur J Implant Refract Surg 1: 15-17.
2. Ohara K (1985) Biomicroscopy of surface deposits resembling foreign-body giant cells on implanted intraocular lenses. Am J Ophthalmol 99: 304-311.
3. Hollick EJ, Spalton DJ, Ursell PG, Pande MV (1998) Biocompatibility of poly(methyl methacrylate), silicone, and AcrySof intraocular lenses: Randomized comparison of the cellular reaction on the anterior lens surface. J Cataract Refract Surg 24: 361-366.
4. Nguyen J, Werner L (1995) Intraocular lenses for cataract surgery. In: Kolb H, Fernandez E, Nelson R, Webvision: The organization of the retina and visual system. University of Utah Health Sciences Center, Salt Lake City (UT).
5. Werner L (2008) Biocompatibility of intraocular lens materials. Curr Opin Ophthalmol 19: 41-49.
6. Öz yol P, Öz yol E, Karel F (2017) Biocompatibility of intraocular lenses. Turk J Ophthalmol 47: 221-225.
7. Foster CS, Stavrou P, Zafirakis P, Rojas B, Tesavibul N, et al. (1999) Intraocular lens removal from patients with uveitis. Am J Ophthalmol 128: 31-37.
8. Shah SM, Spalton DJ (1995) Natural history of cellular deposits on the anterior intraocular lens surface. J Cataract Refract Surg 21: 466-471.
9. Sen HN, Abreu FM, Louis TA, Sugar EA, Altaweel MM, et al. (2016) Cataract surgery outcomes in uveitis: The multicenter uveitis steroid treatment trial. Ophthalmology 123: 183-190.
10. Werner L, Wallace JK, Balendiran V, Shumway C, Ellis N, et al. (2019) Surface deposits mimicking calcification on a hydrophobic acrylic intraocular lens. J Cataract Refract Surg 45: 1036-1039.
11. Werner L (2007) Causes of intraocular lens opacification or discoloration. J Cataract Refract Surg 33: 713-726.
12. Fernández J, Sánchez-García A, Rodríguez-Vallejo M, Piñero DP (2020) Systematic review of potential causes of intraocular lens opacification. Clin Exp Ophthalmol 48: 89-97.
13. Samuelson TW, Chu YR, Kreiger RA (2000) Evaluation of giant-cell deposits on foldable intraocular lenses after combined cataract and glaucoma surgery. J Cataract Refract Surg 26: 817-823.